For the quarter ending 2025-09-30, RIGL made $69,462,000 in revenue. $27,900,000 in net income. Net profit margin of 40.17%.
| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
| Total revenues | 69,462,000 | 101,685,000 | 53,333,000 | 43,565,000 |
| Cost of product sales | 4,753,000 | 4,504,000 | 4,409,000 | 3,907,000 |
| Research and development | 7,353,000 | 6,821,000 | 8,436,000 | 5,829,000 |
| Selling, general and administrative | 28,936,000 | 29,257,000 | 27,715,000 | 28,984,500 |
| Total costs and expenses | 41,042,000 | 40,582,000 | 40,560,000 | 38,720,500 |
| Income from operations | 28,420,000 | 61,103,000 | 12,773,000 | 4,844,500 |
| Interest income | 1,094,000 | 753,000 | 591,000 | 557,500 |
| Interest expense | 1,894,000 | 1,874,000 | 1,853,000 | 1,694,250 |
| Income before income taxes | 27,620,000 | 59,982,000 | 11,511,000 | 3,267,250 |
| (benefit from) provision for income taxes | -280,000 | 369,000 | 65,000 | 220,250 |
| Net income | 27,900,000 | 59,613,000 | 11,446,000 | 3,047,000 |
| Earnings per share, basic | 1.55 | 3.33 | 0.64 | 0.17 |
| Earnings per share, diluted | 1.46 | 3.28 | 0.63 | 0.175 |
| Weighted-average common shares outstanding, basic | 18,038,000 | 17,885,000 | 17,808,000 | -8,785,000 |
| Weighted-average shares outstanding and common stock equivalents | 19,156,000 | 18,162,000 | 18,169,000 | -8,755,000 |
RIGEL PHARMACEUTICALS INC (RIGL)
RIGEL PHARMACEUTICALS INC (RIGL)